Braun Stacey Associates Inc. Takes $14.23 Million Position in Guardian Pharmacy Services, Inc. $GRDN

Braun Stacey Associates Inc. acquired a new position in shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) in the 2nd quarter, Holdings Channel reports. The fund acquired 339,947 shares of the company’s stock, valued at approximately $14,234,000.

Several other institutional investors also recently modified their holdings of the stock. Ameritas Investment Partners Inc. raised its stake in Guardian Pharmacy Services by 26.5% in the third quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock valued at $43,000 after purchasing an additional 345 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Guardian Pharmacy Services in the 2nd quarter worth approximately $43,000. Strs Ohio purchased a new position in Guardian Pharmacy Services in the 4th quarter worth approximately $75,000. Clearstead Advisors LLC grew its stake in Guardian Pharmacy Services by 196.3% in the 4th quarter. Clearstead Advisors LLC now owns 2,628 shares of the company’s stock worth $79,000 after buying an additional 1,741 shares in the last quarter. Finally, State of Wyoming bought a new position in shares of Guardian Pharmacy Services in the 2nd quarter worth $58,000.

Guardian Pharmacy Services Stock Performance

GRDN stock opened at $37.29 on Friday. The company has a market capitalization of $1.86 billion, a PE ratio of 36.20, a price-to-earnings-growth ratio of 1.93 and a beta of 0.10. Guardian Pharmacy Services, Inc. has a one year low of $23.14 and a one year high of $47.02. The company’s 50 day moving average price is $39.89 and its two-hundred day moving average price is $37.88.

Guardian Pharmacy Services (NYSE:GRDN) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.03. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. The company had revenue of $351.77 million during the quarter, compared to analysts’ expectations of $340.45 million. On average, research analysts predict that Guardian Pharmacy Services, Inc. will post 1.19 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Bank of America raised their price objective on shares of Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Weiss Ratings raised Guardian Pharmacy Services from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, August 20th. Oppenheimer raised their price target on Guardian Pharmacy Services from $43.00 to $49.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. Zacks Research lowered Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Wall Street Zen upgraded Guardian Pharmacy Services from a “hold” rating to a “buy” rating in a report on Sunday, August 9th. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Guardian Pharmacy Services has a consensus rating of “Moderate Buy” and an average price target of $43.83.

Guardian Pharmacy Services Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.